Title : Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.

Pub. Date : 2011 Nov 15

PMID : 21844014






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: The combination of riluzole with sorafenib exhibited enhanced antitumor activities in GRM1-expressing melanoma cells harboring either wild-type or mutated B-RAF. Sorafenib B-Raf proto-oncogene, serine/threonine kinase Homo sapiens
2 The combination of riluzole with PLX4720 showed lessened efficacy compared with the combination of riluzole and sorafenib in suppressing the growth of GRM1-expressing cells harboring the B-RAF(V600E) mutation. Sorafenib B-Raf proto-oncogene, serine/threonine kinase Homo sapiens